Alopecia

In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).

Investigators observed disparities in race with persistent chemotherapy-induced alopecia among women with breast cancer.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.

This study highlighted VTE risk factors in a cohort of patients with alopecia areata who were eligible for baricitinib treatment.

This Month in Review summary includes a list of some of the most notable stories in the dermatology field from August 2025.

In this analysis, a variety of alternative therapies for hair loss, such as oils, stem cells, and laser treatments, were highlighted for their potential.

Oral supplementation with a novel dietary AGA-P supplement was shown to increase the clinical efficacy of pharmacological treatments for androgenic alopecia.

This study highlights a significant link between alopecia areata and autoimmune thyroid disease, assessing a large-scale and diverse population.